What Researchers Did
Researchers conducted a randomized controlled clinical trial with 52 severe acute stroke patients to evaluate the effects of normobaric hyperoxia administered for the first 12 hours of admission.
What They Found
The study found no significant differences in sex (P=0.5) or stroke type (P=0.2) between the groups. There was no significant difference in Barthel index scores at discharge or six months (P=0.7); however, a significant difference was observed in modified Rankin Scale scores between groups after treatment.
What This Means for Canadian Patients
If normobaric hyperoxia proves beneficial for severe acute stroke, it could offer a relatively simple, non-invasive treatment option. This could potentially lead to improved neurological outcomes and recovery for Canadian patients experiencing acute stroke.
Canadian Relevance
This study has no direct Canadian connection as it was conducted outside of Canada.
Study Limitations
A key limitation of this study is its relatively small sample size of 52 patients, which may limit the generalizability of the findings.